ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novita Pharmaceuticals and China Resources Double Crane Pharmaceutical Enter into an Exclusive License Agreement to Develop and Commercialize Fascin Inhibitor in China
July 29, 2021Novita today announced that the Company has entered into an exclusive license agreement (the "Agreement") with China Resources Double Crane Pharmaceutical Co., Ltd. (CRDC), for the development and commercialization of Novita's first-in-class fascin. -
Novita Healthcare Ltd to acquire technology platform
July 17, 2017The total consideration for the acquisition will comprise $1 million upfront and a deferred cash earn-out of 4x profit before tax in calendar year 2019
Pharma Sources Insight January 2025
